Contrasting Properties of α7-Selective Orthosteric and Allosteric Agonists Examined on Native Nicotinic Acetylcholine Receptors

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Gill, JasKiran K ^a   Chatzidaki, Anna ^a   Ursu, Daniel ^b   Sher, Emanuele ^b   Millar, Neil S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 NAPTHYL) 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLINE 8 SULFONAMIDE; 4 (4 BROMOPHENYL) 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLINE 8 SULFONAMIDE; AMIDE; BUNGAROTOXIN RECEPTOR; N (1 AZABICYCLO[2.2.2]OCT 3 YL)(5 (2 PYRIDYL)THIOPHENE 2 CARBOXAMIDE); NICOTINIC RECEPTOR; SULFONAMIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL TISSUE; ANURA; ARTICLE; BRAIN NERVE CELL; CALCIUM CELL LEVEL; DESENSITIZATION; FEMALE; FLUORESCENCE; HIPPOCAMPUS; HUMAN; HUMAN CELL; NONHUMAN; PATCH CLAMP; PLURIPOTENT STEM CELL; PRIMARY CELL CULTURE; PROTEIN ANALYSIS; RAT;

ALLOSTERIC REGULATION; ANIMALS; CALCIUM; FEMALE; HIPPOCAMPUS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MOLECULAR IMAGING; NEURONS; NICOTINIC AGONISTS; RATS; RECEPTORS, NICOTINIC; SUBSTRATE SPECIFICITY;

EID: 84873833484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055047     Document Type: Article

References (41)

1. Lester HA, Dibas MI, Dahan DS, Leite JF, Dougherty DA, (2004) Cys-loop receptors: new twists and turns. Trends Neurosci 27: 329-336.
2. Bertrand D, Gopalakrishnan M, (2007) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74: 1155-1163.
3. Williams DK, Wang J, Papke RL, (2011) Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 82: 915-930.
4. Hogg RC, Buisson B, Bertrand D, (2005) Allosteric modulation of ligand-gated ion channels. Biochem Pharmacol 70: 1267-1276.
5. Mazurov AA, Speake JD, Yohannes D, (2011) Discovery and development of α7 nicotinic acetylcholine receptor modulators. J Med Chem 54: 7943-7961.
6. Young GT, Zwart R, Walker AS, Sher E, Millar NS, (2008) Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 105: 14686-14691.
7. Gill JK, Savolainen M, Young GT, Zwart R, Sher E, et al. (2011) Agonist activation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 108: 5867-5872.
8. Gill JK, Dhankher P, Sheppard TD, Sher E, Millar NS, (2012) A series of α7 nicotinic acetylcholine receptor allosteric modulators with close chemical similarity but diverse pharmacological properties. Mol Pharmacol 81: 710-718.
9. Couturier S, Bertrand D, Matter JM, Hernandez MC, Bertrand S, et al. (1990) A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTX. Neuron 5: 847-856.
10. Jindrichova M, Lansdell SJ, Millar NS, (2012) Changes in temperature have opposing effects on current amplitude in α7 and α4β2 nicotinic acetylcholine receptors. PLoS ONE 7: 10.1371/journal.pone.0032073.
11. Collins T, Young GT, Millar NS, (2011) Competitive binding at a nicotinic receptor transmembrane site of two α7-selective positive allosteric modulators with differing effects on agonist-evoked desensitization. Neuropharmacol 61: 1306-1313.
12. Faghih R, Gopalakrishnan M, Briggs CA, (2008) Allosteric modulators of the α7 nicotinic acetylcholine receptor. J Med Chem 51: 701-712.
13. Wallace TL, Porter RHP, (2011) Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 82: 891-903.
14. Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P, (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identification, and therapeutic inspirations. J Med Chem 48: 4705-4745.
15. Arneric SP, Holladay M, Williams M, (2007) Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 74: 1092-1101.
16. Phillips E, Schmiesing R (2001) Novel biarylcarboxamides. International patent number: WO 01/60821.
17. Cilia J, Cluderay JE, Robbins MJ, Reavill C, Southam E, et al. (2005) Reversal of isolation-rearing-induced PPI deficits by an α7 nicotinic receptor agonist. Psycopharmacol 182: 214-219.
18. Visanji NP, O'Neill MJ, Duty S, (2006) Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacol 51: 506-516.
19. Dickinson JA, Hanrott KE, Mok MHS, Kew JNC, Wonnacott S, (2007) Differential coupling of α7 and non-α7 nicotinic acetylcholine receptors to calcium-induced calcium release and voltage-operated calcium channels in PC12 cells. J Neurochem 100: 1089-1096.
20. Dickinson JA, Kew JNC, Wonnacott S, (2008) Presynaptic α7- and β2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distince cellular mechanisms. Mol Pharmacol 74: 348-359.
21. De Filippi G, Broad LM, Zwart R, Baldwinson T, Felthouse C, et al. (2002) Pharmacological characterisation and in vitro physiological effects of new α7 nicotinic acetylcholine receptor agonists. Soc Neurosci Abstracts: 137.135.
22. O'Neill MJ, Moore NA, McKinzie DL, Keenan M, Wishart G, et al. (2002) Behavioural prfiling of two potent alpha 7 nicotinic acetylcholine receptor agonists. Soc Neurosci Abstracts: 137.136.
23. Medhurst SJ, Hatcher JP, Hille CJ, Bingham S, Clayton NM, et al. (2008) Activation of the α7-nicotinic acetylcholine receptor reverses complete freund adjuvant-induced mechanical hyperalgesia in the rat via a cemtral site of action. J Pain 9: 580-587.
24. Munro G, Hansen RR, Erichsen HK, Timmermann DB, Christensen JK, et al. (2012) The α7nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat. Br J Pharmacol doi: 10.1111/j.1476-5381.2012.02003.x.
25. Grønlien JH, Håkerud M, Ween H, Thorin-Hagene K, Briggs CA, et al. (2007) Distinct profiles of α7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72: 715-724.
26. daCosta CJB, Free CR, Corradi J, Bouzat C, Sine SM, (2011) Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation. J Neurosci 31: 13870-13879.
27. Pałczyńska MM, Jindrichova M, Gibb AJ, Millar NS (2012) Activation of α7 nicotinic receptors by orthosteric and allosteric agonists: influence on single-channel kinetics and conductance. Mol Pharmacol: doi:10.1124/mol.1112.080259.
28. Haydar SN, Dunlop J, (2010) Neuronal nicotinic acetylcholine receptors- targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Curr Top Med Chem 10: 144-152.
29. Arias HR, (2000) Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. Neurochem Int 36: 595-645.
30. Millar NS, Gotti C, (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacol 56: 237-246.
31. Le Novère N, Corringer P-J, Changeux J-P, (2002) The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol 53: 447-456.
32. Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, et al. (2005) A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25: 4396-4405.
33. Lansdell SJ, Collins T, Goodchild J, Millar NS, (2012) The Drosophila nicotinic acetylcholine receptor subunits Dα5 and Dα7 form functional homomeric and heteromeric ion channels. BMC Neurosci 13: 73 doi: 10.1186/1471-2202-1113-1173.
34. Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, et al. (2009) Old and new pharmacology: positive allosteric modulation of the α7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine2B/C receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide). J Pharmacol Exp Ther 328: 766-776.
35. Dinklo T, Shaban H, Thuring JW, Lavreysen H, Stevens KE, et al. (2011) Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolethanol (JNJ-1930942), a novel positive allosteric modulator of the α7 nicotinic acetylcholine receptor. J Pharmacol Exp Ther 336: 560-574.
36. Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, et al. (2007) An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323: 294-307.
37. Malysz J, Grønlien JH, Anderson DJ, Håkerud M, Thorin-Hagene K, et al. (2009) In vitro pharmacological characterization of a novel allosteric modulator of the α7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther 330: 257-267.
38. Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, et al. (1996) Comparative structure of human neuronal α2-α7 and β2-β4 nicotinic acetylcholine receptor subunits and functional expression of the α2, α3, α4, α7, β2, and β4 subunits. J Mol Neurosci 7: 217-228.
39. Broadbent S, Groot-Kormelink PJ, Krashia PA, Harkness PC, Millar NS, et al. (2006) Incorporation of the β3 subunit has a dominant-negative effect on the function of recombinant central-type neuronal nicotinic receptors. Mol Pharmacol 70: 1350-1356.
40. Croxen R, Young C, Slater C, Haslam S, Brydson M, et al. (2001) End-plate γ- and ε-subunit mRNA levels in AChR deficienct syndrome due to ε-subunit null mutations. Brain 124: 1362-1372.
41. Young GT, Broad LM, Zwart R, Astles PC, Bodkin M, et al. (2007) Species selectivity of a nicotinic acetylcholine receptor agonist is conferred by two adjacent extracellular β4 amino acids that are implicated in the coupling of binding to channel gating. Mol Pharmacol 71: 389-397.